AtlasInfectionsNeglected tropical diseases and malaria

Malaria

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Mefloquine approved (FDA)1992 — Atovaquone approved (FDA)1992 — Halofantrine approved (FDA)2000 — Proguanil approved (FDA)2005 — Quinine approved (FDA)2009 — Artemether approved (FDA)2009 — Lumefantrine approved (FDA)2018 — Tafenoquine approved (FDA)2020 — Artesunate approved (FDA)
1989: Drug approval — Mefloquine approved (FDA). 1992: Drug approval — Atovaquone approved (FDA). 1992: Drug approval — Halofantrine approved (FDA). 2000: Drug approval — Proguanil approved (FDA). 2005: Drug approval — Quinine approved (FDA). 2009: Drug approval — Artemether approved (FDA). 2009: Drug approval — Lumefantrine approved (FDA). 2018: Drug approval — Tafenoquine approved (FDA). 2020: Drug approval — Artesunate approved (FDA)

What's being tested now

2010: 1 trials started2015: 1 trials started2016: 2 trials started2019: 1 trials started2021: 2 trials started2022: 3 trials started2023: 10 trials started2024: 24 trials started2025: 29 trials started2026: 31 trials started20102020202631

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 96 active Malaria trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.